Literature DB >> 2007941

Comparative efficacy of ceftriaxone and ampicillin for treatment of severe shigellosis in children.

I Varsano1, T Eidlitz-Marcus, M Nussinovitch, I Elian.   

Abstract

In a prospective randomized open study, ceftriaxone, 50 mg/kg per day, was compared with ampicillin, 100 mg/kg per day, both given for a period of 5 days, for the treatment of 40 children whose mean (+/- SD) age was 4.5 +/- 3.2 years and who had severe dysentery caused by Shigella organisms. Twenty patients were treated with ceftriaxone and 20 with ampicillin. Both drugs were initially given intravenously for a period of 1 to 2 days and were continued intramuscularly, in the case of ceftriaxone, or orally, in the patients receiving ampicillin. All Shigella organisms isolated were susceptible to ceftriaxone; 28% were resistant to ampicillin. The diarrhea persisted for a mean (+/- SD) period of 2.5 +/- 1.0 days in the ceftriaxone-treated patients versus 6.8 +/- 6.3 days in the ampicillin-treated patients (p less than 0.005). At the end of the 5 days of therapy, stool cultures for Shigella organisms were negative in 12 (60%) of the 20 patients from the ampicillin group and in all the children (100%) from the ceftriaxone group (p less than 0.001). Bacteriologic relapses were observed in eight (40%) of the patients treated with ampicillin but in none of the children treated with ceftriaxone (p less than 0.001). In instances of clinical or bacteriologic failure in the ampicillin group, retreatment was instituted in most of the cases with ceftriaxone; persistent clearing of the Shigella organisms from the stool was finally achieved after a mean (+/- SD) period of 11.75 +/- 9.4 days after therapy was started, as compared with 1.85 +/- 0.6 days in the ceftriaxone-treated patients (p less than 0.001). We conclude that in children with severe shigellosis, treatment with ceftriaxone for 5 days is effective and better than use of ampicillin for clinical cure and eradication of the Shigella organisms from the stool.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2007941     DOI: 10.1016/s0022-3476(05)83392-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  9 in total

1.  An update on vaccines against Shigella.

Authors:  Shai Ashkenazi; Dani Cohen
Journal:  Ther Adv Vaccines       Date:  2013-09

2.  Options for treating resistant Shigella species infections in children.

Authors:  Sharon M Erdman; Elizabeth E Buckner; Janet F Hindler
Journal:  J Pediatr Pharmacol Ther       Date:  2008-01

Review 3.  Antibiotic therapy for Shigella dysentery.

Authors:  Prince Rh Christopher; Kirubah V David; Sushil M John; Venkatesan Sankarapandian
Journal:  Cochrane Database Syst Rev       Date:  2010-08-04

Review 4.  Antibiotics for the treatment of dysentery in children.

Authors:  Beatrix S Traa; Christa L Fischer Walker; Melinda Munos; Robert E Black
Journal:  Int J Epidemiol       Date:  2010-04       Impact factor: 7.196

5.  Increasing antimicrobial resistance of Shigella isolates in Israel during the period 1984 to 1992.

Authors:  S Ashkenazi; M May-Zahav; J Sulkes; R Zilberberg; Z Samra
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

Review 6.  Comparison of resistance to third-generation cephalosporins in Shigella between Europe-America and Asia-Africa from 1998 to 2012.

Authors:  B Gu; M Zhou; X Ke; S Pan; Y Cao; Y Huang; L Zhuang; G Liu; M Tong
Journal:  Epidemiol Infect       Date:  2015-01-02       Impact factor: 4.434

Review 7.  Antibiotics for the treatment of Cholera, Shigella and Cryptosporidium in children.

Authors:  Jai K Das; Anum Ali; Rehana A Salam; Zulfiqar A Bhutta
Journal:  BMC Public Health       Date:  2013-09-17       Impact factor: 3.295

8.  Increasing spectrum in antimicrobial resistance of Shigella isolates in Bangladesh: resistance to azithromycin and ceftriaxone and decreased susceptibility to ciprofloxacin.

Authors:  Mahbubur Rahman; Shereen Shoma; Harunur Rashid; Shams El Arifeen; A H Baqui; A K Siddique; G B Nair; D A Sack
Journal:  J Health Popul Nutr       Date:  2007-06       Impact factor: 2.000

9.  Newly Emerged Serotype 1c of Shigella flexneri: Multiple Origins and Changing Drug Resistance Landscape.

Authors:  Pawan Parajuli; Bui Quang Minh; Naresh K Verma
Journal:  Genes (Basel)       Date:  2020-09-03       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.